Jörg Felix Hipp

Jörg Felix Hipp

Auto-generated profile, based on publicly available information

Jörg Felix Hipp

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2012 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JHJoerg F Hipp
Joerg F Hipp
DHDavid J Hawellek
David J Hawellek
MCMaurizio Corbetta
Maurizio Corbetta
MSMarkus Siegel
Markus Siegel
AEAndreas K Engel
Andreas K Engel

1 January 2011 in Neuron
Verified
Journal Article
Closed access
JHJoerg F. Hipp
Joerg F. Hipp
AEAndreas K. Engel
Andreas K. Engel
MSMarkus Siegel
Markus Siegel

1 July 2018 in Trends in Neurosciences
Verified
Journal Article
Closed access
JSJan Stefan Sanders
Jan Stefan Sanders
ACArthur J. Campbell
Arthur J. Campbell
JCJeffrey R. Cottrell
Jeffrey R. Cottrell
RMRikke S. Moller
Rikke S. Moller
FWFlorence F. Wagner
Florence F. Wagner
KBKevin J. Bender
Kevin J. Bender

23 June 2017 in Molecular Autism
Verified
Journal Article
Open access
PDF file
ELEva Loth
Eva Loth
TCTony Charman
Tony Charman
LMLuke Mason
Luke Mason
JTJulian Tillmann
Julian Tillmann
EJEmily J. H. Jones
Emily J. H. Jones
JBJan K. Buitelaar
Jan K. Buitelaar
The tremendous clinical and aetiological diversity among individuals with autism spectrum disorder (ASD) has been a major obstacle to the development of new treatments, as many may only be effective in particular subgroups. Precision medicine approaches aim to overcome this challenge by combining pathophysiologically based treatments with stratification biomarkers that predict which treatment may be most beneficial for particular individuals. However, so far, we have no single validated stratification biomarker for ASD. This may be due to the fact that most research studies primarily have focused on the identification of mean case-control differences, rather than within-group variability, and included small samples that were underpowered for stratification approaches. The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD. LEAP includes 437 children and adults with ASD and 300 individuals with typical development or mild intellectual disability. Using an accelerated longitudinal design, each participant is comprehensively characterised in terms of clinical symptoms, comorbidities, functional outcomes, neurocognitive profile, brain structure and function, biochemical markers and genomics. In addition, 51 twin-pairs (of which 36 had one sibling with ASD) are included to identify genetic and environmental factors in phenotypic variability. Here, we describe the demographic characteristics of the cohort, planned analytic stratification approaches, criteria and steps to validate candidate stratification markers, pre-registration procedures to increase transparency, standardisation and data robustness across all analyses, and share some ‘lessons learnt’. A clinical characterisation of the cohort is given in the companion paper (Charman et al., accepted). We expect that LEAP will enable us to confirm, reject and refine current hypotheses of neurocognitive/neurobiological abnormalities, identify biologically and clinically meaningful ASD subgroups, and help us map phenotypic heterogeneity to different aetiologies.

7 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DHDavid J. Hawellek
David J. Hawellek
JHJoerg F. Hipp
Joerg F. Hipp
CLChristopher M. Lewis
Christopher M. Lewis
MCMaurizio Corbetta
Maurizio Corbetta
AEAndreas K. Engel
Andreas K. Engel
Correlations in spontaneous brain activity provide powerful access to large-scale organizational principles of the CNS. However, making inferences about cognitive processes requires a detailed understanding of the link between these couplings and the structural integrity of the CNS. We studied the impact of multiple sclerosis, which leads to the severe disintegration of the central white matter, on functional connectivity patterns in spontaneous cortical activity. Using a data driven approach based on the strength of a salient pattern of cognitive pathology, we identified distinct networks that exhibit increases in functional connectivity despite the presence of strong and diffuse reductions of the central white-matter integrity. The default mode network emerged as a core target of these connectivity modulations, showing enhanced functional coupling in bilateral inferior parietal cortex, posterior cingulate, and medial prefrontal cortex. These findings imply a complex and diverging relation of anatomical and functional connectivity in early multiple sclerosis and, thus, add an important observation for understanding how cognitive abilities and CNS integrity may be reflected in the intrinsic covariance of functional signals.

1 January 2013 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
JHJoerg F. Hipp
Joerg F. Hipp
MSMarkus Siegel
Markus Siegel
EEG is the most common technique for studying neuronal dynamics of the human brain. However, electromyogenic artifacts from cranial muscles and ocular muscles executing involuntary microsaccades compromise estimates of neuronal activity in the gamma band (>30 Hz). Yet, the relative contributions and practical consequences of these artifacts remain unclear. Here, we systematically dissected the effects of these different artifacts on studying visual gamma-band activity with EEG on the sensor and source level, and show strategies to cope with these confounds. We found that cranial muscle activity prevented a direct investigation of neuronal gamma-band activity at the sensor level. Furthermore, we found prolonged microsaccade-related artifacts beyond the well-known transient EEG confounds. We then show that if electromyogenic artifacts are carefully accounted for, the EEG nonetheless allows for studying visual gamma-band activity even at the sensor level. Furthermore, we found that source analysis based on spatial filtering does not only map the EEG signals to the cortical space of interest, but also efficiently accounts for cranial and ocular muscle artifacts. Together, our results clarify the relative contributions and characteristics of myogenic artifacts confounding visual gamma-band activity in EEG, and provide practical guidelines for future experiments.